PA8622601A1 - Sales de o-desmetilvenlafaxina de multiples particulas y sus usos - Google Patents

Sales de o-desmetilvenlafaxina de multiples particulas y sus usos

Info

Publication number
PA8622601A1
PA8622601A1 PA20058622601A PA8622601A PA8622601A1 PA 8622601 A1 PA8622601 A1 PA 8622601A1 PA 20058622601 A PA20058622601 A PA 20058622601A PA 8622601 A PA8622601 A PA 8622601A PA 8622601 A1 PA8622601 A1 PA 8622601A1
Authority
PA
Panama
Prior art keywords
demetilvenlafaxine
salts
multiple particles
odv
fomiate
Prior art date
Application number
PA20058622601A
Other languages
English (en)
Spanish (es)
Inventor
Syed M Shah
Christopher Richard Diorio
Mahdi B Fawzi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PA8622601A1 publication Critical patent/PA8622601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PA20058622601A 2004-02-06 2005-02-03 Sales de o-desmetilvenlafaxina de multiples particulas y sus usos PA8622601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54238404P 2004-02-06 2004-02-06

Publications (1)

Publication Number Publication Date
PA8622601A1 true PA8622601A1 (es) 2005-10-28

Family

ID=34860300

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058622601A PA8622601A1 (es) 2004-02-06 2005-02-03 Sales de o-desmetilvenlafaxina de multiples particulas y sus usos

Country Status (21)

Country Link
US (1) US20050175698A1 (https=)
EP (2) EP2052717A1 (https=)
JP (1) JP2007520553A (https=)
KR (1) KR20060132891A (https=)
CN (1) CN1917860A (https=)
AR (1) AR050230A1 (https=)
AU (1) AU2005212166A1 (https=)
BR (1) BRPI0507372A (https=)
CA (1) CA2554559A1 (https=)
CR (1) CR8535A (https=)
EC (1) ECSP066827A (https=)
IL (1) IL177052A0 (https=)
NO (1) NO20063963L (https=)
PA (1) PA8622601A1 (https=)
PE (1) PE20050771A1 (https=)
RU (1) RU2006127437A (https=)
SG (1) SG149894A1 (https=)
SV (1) SV2005002008A (https=)
TW (1) TW200528092A (https=)
WO (1) WO2005077340A1 (https=)
ZA (1) ZA200606526B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
AU2002250058B2 (en) 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
US20080103171A1 (en) * 2004-12-27 2008-05-01 Astellas Pharma Inc. Stable Particular Pharmaceutical Composition of Solifenacin or Salt Thereof
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US7595340B2 (en) 2005-07-15 2009-09-29 Wyeth Serotonin and norepinephrine reuptake inhibitor and uses thereof
US20070014859A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly bioavailable oral delayed release dosage forms of O-desmethylvenlafaxine succinate
US20070015828A1 (en) * 2005-07-15 2007-01-18 Wyeth Highly selective serotonin and norepinephrine dual reuptake inhibitor and use thereof
US7687520B2 (en) 2005-07-15 2010-03-30 Wyeth Llc Serotonin and norepinephrine reuptake inhibitors and uses thereof
TW200806282A (en) * 2006-05-05 2008-02-01 Wyeth Corp Solid dosage formulations
EP1870395A1 (en) 2006-06-19 2007-12-26 KRKA, D.D., Novo Mesto Process for preparation of o-desmethylvenlafaxine and its analogue
TR200909798T1 (tr) * 2007-07-12 2010-05-21 Dr. Reddy's Laboratories Ltd. O-desmetilvenlafaksin.
CA2702664A1 (en) * 2007-10-16 2009-04-23 Alphapharm Pty Ltd Controlled-release pharmaceutical formulation
US20110046231A1 (en) * 2007-10-22 2011-02-24 Actavis Group Ptc Ehf Solid forms of (±)-o-desmethylvenlafaxine salts
MX2012010659A (es) 2010-03-31 2013-03-05 Wockhardt Ltd Composicion farmaceutica de liberacion modificada que comprende desvenlafaxina o sus sales.
KR20140030156A (ko) 2011-04-12 2014-03-11 루핀 리미티드 방출-조절되는 데스벤라팍신 약학 조성물
WO2013164559A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3081496A (en) * 1959-10-15 1963-03-19 John F Moore Method of forming flexible sheets of cured foamed rubber
AT294000B (de) * 1965-01-11 1971-11-10 Diersch & Schroeder Verfahren zur Herstellung von Teppichen oder Läufern
US3885257A (en) * 1972-10-30 1975-05-27 Evans Ronald J P Pressure controlled resilient supporting structure
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
US4603445A (en) * 1983-09-09 1986-08-05 Span-America Medical Systems, Inc. Support pad and method of manufacture
US5099627A (en) * 1990-09-28 1992-03-31 Benjamin Obdyke Incorporated Ventilated roof construction and method
US5203703A (en) * 1991-08-27 1993-04-20 Schneiderman Marc J Deglutition training method and apparatus
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6162309A (en) * 1998-04-21 2000-12-19 Burlington Industries, Inc. Reinforced foam backed carpet
US6197828B1 (en) * 1998-12-01 2001-03-06 Sepracor, Inc. Derivatives of (+)-venlafaxine and methods of preparing and using the same
US6342533B1 (en) * 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
PL350924A1 (en) * 1999-04-06 2003-02-10 Sepracor Inc Derivatives of venlafaxine and methods of preparing and using the same
WO2000076955A1 (en) * 1999-06-15 2000-12-21 American Home Products Corporation Enantiomers of o-desmethyl venlafaxine
US6863972B2 (en) * 2001-01-09 2005-03-08 Crane Plastics Company Llc Synthetic wood component having a foamed polymer backing
AU2002250058B2 (en) * 2001-02-12 2007-08-16 Wyeth Llc Novel succinate salt of O-desmethyl-venlafaxine
US20030152741A1 (en) * 2002-02-05 2003-08-14 Robbins Jeffrey L. Patterned polyurethane foam and a process for the production of tufted goods with patterned foam backing
US20030190352A1 (en) * 2002-03-28 2003-10-09 Synthon Bv Compositions of venlafaxine base
AU2003247515A1 (en) 2002-06-10 2003-12-22 Wyeth Novel formate salt of o-desmethyl-venlafaxine
JP2004359665A (ja) * 2003-05-30 2004-12-24 Rohm & Haas Co 生体利用性増強剤を含有する治療組成物

Also Published As

Publication number Publication date
SV2005002008A (es) 2005-11-04
EP2052717A1 (en) 2009-04-29
JP2007520553A (ja) 2007-07-26
IL177052A0 (en) 2006-12-10
NO20063963L (no) 2006-09-05
CN1917860A (zh) 2007-02-21
KR20060132891A (ko) 2006-12-22
ECSP066827A (es) 2006-11-24
PE20050771A1 (es) 2005-11-15
AR050230A1 (es) 2006-10-11
US20050175698A1 (en) 2005-08-11
RU2006127437A (ru) 2008-03-20
TW200528092A (en) 2005-09-01
SG149894A1 (en) 2009-02-27
WO2005077340A1 (en) 2005-08-25
AU2005212166A1 (en) 2005-08-25
CA2554559A1 (en) 2005-08-25
EP1711167A1 (en) 2006-10-18
ZA200606526B (en) 2010-03-31
BRPI0507372A (pt) 2007-07-10
CR8535A (es) 2006-12-07

Similar Documents

Publication Publication Date Title
PA8622601A1 (es) Sales de o-desmetilvenlafaxina de multiples particulas y sus usos
ECSP077280A (es) Moduladores de quinasa de pirrolo-piridina
AR054213A1 (es) Composiciones de aceites de semillas
CO6362050A2 (es) Vectores de terapia de gen y desaminasas citosina
AR060978A1 (es) Anticuerpos e inmunoconjugados y sus usos
MX2009010284A (es) Inhibidores de la tirosina-cinasa de bruton.
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
MX2016005574A (es) Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
GT200500237A (es) Derivados de pirimidina
DE602004026303D1 (de) Behandlung von entzündlichen erkrankungen
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
AR039170A1 (es) Co-granulos de dha y romero y metodos de uso
MX337059B (es) Metodos y composiciones para modular la hemostasia.
FR2870125B1 (fr) Formulation du type spot-on utile en cosmetologie et en dermatologie
DK1764372T3 (da) Vævsinhibitor af metalloproteinaser (TIMP) bundet til glycosylphosphatidylinositol (GPI)-ankre til behandling af cancer
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
AR085396A1 (es) Medio de cultivo celular para exposicion uvc y metodos relacionados con el mismo
CO2022005889A2 (es) Derivados terapéuticos de interleucina-22
BRPI0515518A (pt) análogos de loxapina e métodos de usos dos mesmos
AR058177A1 (es) Composiciones para el tratamiento del cabello
CL2007001748A1 (es) Compuesto derivado de 2-arilamino-4-aminopirimidinas, inhibidores de la proteina quinasa c-alfa; composiciones farmaceuticas que los contienen; y su uso para tratar o prevenir la diabetes, el cancer, enfermedades cardiovasculares y otras.
CL2020002650A1 (es) Enzimas quinureninasa humanas y sus usos
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
AR061247A1 (es) Enzima dmo modificada y metodos de uso de la misma
EP1529521A3 (de) Verwendung von hydrierten Sojaglyceriden in kosmetische Zubereitungen